Everyone Is Talking About This Stock. Is It a Good Long-Term Option?

Moderna (NASDAQ: MRNA) has been a stock to watch -- and buy -- ever since it entered the coronavirus vaccine race. The biotech company brought a vaccine to market in less than a year. And it's delivered billions of dollars in revenue and profit thanks to that product. As a result, the shares have soared. They climbed 1,200% over the past two years.

But the stock has lost some of its sparkle in recent times. It's down more than 60% since its peak in August. That's as investors worry about revenue prospects post-pandemic. Moderna has been great in the short and medium term. But, today, it's fair to ask: Is this vaccine superstar a good long-term option? Let's find out.

Image source: Getty Images.

Continue reading

Source Fool.com